This nearly four-month delay was observed on top of the standard of care, highlighting the drug’s potential to reduce the frequency and severity of painful VOC events in people with sickle cell disease (SCD).

The Phase 3 HIBISCUS trial showed that etavopivat significantly delayed the time to first vaso-occlusive crisis (VOC), with patients experiencing their first crisis at 38.4 weeks compared to 20.9 weeks for those receiving placebo, according to Novo Nordisk officials.

The trial enrolled 385 participants aged 12 years and older who were treated over a 52-week period with a once-daily 400-mg oral dose of etavopivat, a pyruvate kinase-R (PKR) activator. The drug’s mechanism works by preventing the sickling of red blood cells, which is the underlying cause of vaso-occlusive crises, according to company statements and published trial data. Both co-primary endpoints of the study were met, with etavopivat demonstrating a 27% reduction in annualized VOC rate and a superior hemoglobin response compared to placebo.

Specifically, 48.7% of patients treated with etavopivat achieved a hemoglobin increase greater than 1 gram per deciliter at 24 weeks, compared to 7.2% in the placebo group, representing a 41.2% adjusted rate difference, Novo Nordisk reported. This hemoglobin improvement is a key measure of treatment efficacy and supports the drug’s potential to improve oxygen delivery and reduce the complications associated with sickle cell disease.

Clinical safety data from the HIBISCUS trial indicated that etavopivat was well tolerated, with a safety profile consistent with previous studies of the drug. No major safety concerns emerged that would impede the regulatory approval process, according to company officials. The inclusion of adolescents aged 12 years and older alongside adults provided a broad assessment of the drug’s safety and efficacy across a wide age range.

Novo Nordisk acquired etavopivat in September 2022 as part of its $1.1 billion purchase of Forma Therapeutics, the original developer of the drug candidate. The acquisition added etavopivat to Novo Nordisk’s pipeline as a first-in-class oral treatment for sickle cell disease, designed to improve patient convenience and compliance with a once-daily tablet formulation. Company leadership has described etavopivat as a potential “first and best-in-class therapy” for SCD.

The company plans to submit regulatory filings for etavopivat in the third or fourth quarter of 2026, with FDA approval expected in the second half of that year, Novo Nordisk said. Detailed results from the HIBISCUS trial are scheduled to be presented at a scientific conference in 2026.

Analysts from Truist Securities noted that the trial results create “separation amongst PK class candidates,” although no direct head-to-head comparisons have been conducted between etavopivat and competing drugs such as mitapivat. Mitapivat, another PKR activator, showed a 40.6% hemoglobin response rate in its Phase 3 data released in November 2025. Cross-trial comparisons remain inconclusive, according to market analysts, but the data put pressure on other drugmakers developing therapies for sickle cell disease.

Sickle cell disease is a genetic blood disorder characterized by the sickling of red blood cells, which can block blood vessels and cause severe pain in bones, chest, back, or joints. Vaso-occlusive crises are a major cause of morbidity and reduced quality of life for millions of patients worldwide. Current therapeutic options are limited, creating a significant unmet medical need for effective and well-tolerated treatments.

Novo Nordisk’s development of etavopivat aims to address this gap by providing a novel oral therapy that targets the underlying pathophysiology of SCD. The company’s acquisition of Forma Therapeutics and subsequent Phase 3 success represent a strategic effort to expand treatment options for this patient population.

ET-600, a proprietary oral solution formulation of desmopressin, has been developed by Eton Pharmaceuticals, Inc. (NASDAQ: ETON) specifically to treat central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D). This clearance marks a significant milestone in pediatric endocrinology, as ET-600 is targeted at approximately 3,000 pediatric patients in the United States who suffer from this rare condition.

Although treatment options for arginine vasopressin deficiency have been limited, the FDA has recently granted clearance for ET-600, a novel therapeutic agent designed to address this condition.

The FDA’s clearance of ET-600 follows the acceptance of the New Drug Application (NDA) and the Prescription Drug User Fee Act (PDUFA) target action date of February 25, 2026. This regulatory approval signifies that ET-600 meets the FDA’s stringent requirements for safety and efficacy in treating AVP-D in children. Importantly, ET-600 is designed to offer precise, titratable doses in an oral liquid form, addressing a critical unmet need in the management of this disorder. Prior to ET-600, treatment options were limited to off-label, compounded liquid suspensions or the cutting of fractional tablets, both of which presented challenges in dosing accuracy and safety.

The introduction of ET-600 offers a unique solution as the only oral liquid formulation approved for pediatric patients with AVP-D, improving dosing precision over current methods. This is particularly relevant for children, where accurate dosing is paramount to effective management and reduction of adverse effects. The oral liquid format of ET-600 is expected to enhance caregiver compliance and simplify administration, thereby improving overall treatment outcomes. Moreover, ET-600’s formulation and delivery method directly respond to the significant gap in available therapies for this patient population, which has long relied on suboptimal alternatives.

From a commercial perspective, Eton Pharmaceuticals is preparing for a potential launch of ET-600 in the first quarter of 2026, following FDA clearance. The company’s strategic move to secure patent protection for ET-600’s formulation until 2044, along with an additional patent application under review, positions ET-600 for long-term market exclusivity. This exclusivity is expected to support a high-value product opportunity, as no competing oral liquid options currently exist for AVP-D treatment. For more information, see shop on Amazon.

Financially, Eton Pharmaceuticals has demonstrated robust growth, with a market capitalization of $386 million and a 323% return over the past year. The company reported a 41% increase in revenue over the last twelve months, including a 117% year-over-year increase in Q1 2025 revenue to $17.3 million. Analysts anticipate continued sales growth driven by the launch of ET-600 and its capacity to fulfill a critical pediatric therapeutic need. The FDA’s clearance of ET-600 not only represents a breakthrough in treatment for arginine vasopressin deficiency but also signals a promising commercial future for Eton Pharmaceuticals in the rare disease space.

This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no additional cost to you.